GLP-1 Showdown: Tirzepatide, Semaglutide, and a New Weekly Contender

Until recently, comparing tirzepatide and semaglutide for weight loss meant squinting across separate trials with different populations, durations, and endpoints. The new network meta-analysis published in Cureus does the statistical bridging work: eight RCTs, 7,179 non-diabetic adults with obesity, every active arm benchmarked against placebo using a random-effects model, with funnel plots and Egger-type regression to interrogate small-study effects.

The headline ranking is unambiguous. Tirzepatide at its maximum tolerated dose produced the largest mean reduction in body weight — a difference of −20.90% versus placebo (95% CI: −24.93 to −16.87) — followed by tirzepatide 15 mg at −18.08% (95% CI: −20.38 to −15.78). The lower tirzepatide doses and semaglutide 2.4 mg also beat placebo significantly; they simply did less of it. For a class that often gets discussed as monolithic, that dose-response gradient is the part worth internalizing.

Tirzepatide's mechanistic edge — agonism at both the GLP-1 and GIP receptors — has been the working hypothesis for why it outperforms selective GLP-1 agonists on weight. The network meta-analysis is consistent with that idea: even at 5 mg, tirzepatide is meaningfully active, and the curve steepens as the dose climbs. Secondary endpoints — waist circumference and the proportion of participants reaching ≥15% weight loss — track the same ranking.

The catch, and it is a real one, is tolerability. The analysis tracked discontinuation due to adverse events and gastrointestinal side effects as part of its safety read. All incretin therapies trade some GI burden for metabolic effect; the question for any individual is whether the dose that delivers the response they want is the dose they can actually stay on. That is a clinician conversation, not a forum one.

The second piece of evidence is narrower but interesting. Efsubaglutide Alfa is a novel, long-acting, once-weekly GLP-1 receptor agonist. The pivotal phase 2b/3 SUPER2 trial settled on the 3 mg dose, but 155 patients had already been randomized to 1 mg before the interim analysis — the so-called "overrun" cohort. A new post-hoc analysis in Diabetes, Obesity & Metabolism follows those patients through 24 weeks of double-blind 1 mg dosing.

The glycemic numbers are substantial. HbA1c dropped by −1.69% at week 24 on Efsubaglutide Alfa 1 mg versus −0.74% on placebo, a placebo-corrected difference of −0.95% (p < 0.0001). Fasting plasma glucose fell by −2.09 mmol/L versus −0.50 mmol/L on placebo, and 56.3% of patients reached HbA1c <7.0% compared with 11.1% on placebo — an odds ratio of 8.3.

The weight signal, at this lower dose, is the part biohackers will want to read carefully. Body weight reduction was modest and not statistically significant: −2.8% versus −1.3% on placebo (LSM −0.72 kg; p = 0.137). That is consistent with a molecule whose lower dose is doing useful glycemic work but is not, at 1 mg, a weight-loss instrument on par with what the network meta-analysis describes for tirzepatide.

Put together, the two papers support a few defensible statements. First, within non-diabetic obesity, the comparative ranking of tirzepatide doses over semaglutide 2.4 mg is now backed by a formal network meta-analysis rather than cross-trial guesswork. Second, the incretin pipeline is not finished: a new weekly agonist has now published phase 2b/3-adjacent data with a clear glycemic signal, even if its lower-dose weight effect is modest. Third — and this is the part the quantified-self crowd tends to underweight — "strongest mean effect" and "right drug for you" are not the same sentence. Dose tolerability, comorbidities, access, and what happens when the drug is eventually stopped all sit outside what these trials measured.

The honest read is that the GLP-1 era is maturing from a single-drug story into a class with internal hierarchy and credible new entrants. The data are getting better. The decisions still belong with a clinician.